Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
On September 23, 2026, Sarepta Therapeutics, Inc. entered into a settlement agreement with REGENXBIO Inc., the Trustees of the University of Pennsylvania, Catalent, Inc. and its subsidiary Sarepta Therapeutics Three, LLC, regarding the resolution of pending patent infringement litigations and an appeal from inter partes review proceedings.
Sarepta will pay REGENXBIO a lump sum of $39.0 million within ten days of the agreement’s effective date. Sarepta recorded a $39.0 million litigation contingency charge related to the anticipated settlement for the three and six months ended June 30, 2026. REGENXBIO and the Trustees released Sarepta, Catalent and their affiliates from specified past patent claims concerning Sarepta gene therapy products using an AAVrh74-based capsid, including ELEVIDYS, and agreed not to sue over qualifying claims. REGENXBIO also agreed not to sue over certain claims concerning patents or applications covering the existing form of ELEVIDYS or the AAVrh74 capsid sequence. The agreement provides for dismissal, withdrawal or other disposal of the litigations with prejudice, and each party will bear its own related costs, expenses and attorneys’ fees.
Sarepta Therapeutics, Inc. (SRPT) reported that its Chief Financial Officer, Ryan Ho-Yan Wong, had 13,272 shares of common stock withheld on September 4, 2026 to pay tax liabilities tied to the vesting of restricted stock units granted on September 3, 2025. After this withholding, he directly holds 121,792 shares of Sarepta common stock. No transactions were made under a Rule 10b5-1 trading plan.
Sarepta Therapeutics, Inc. (SRPT) reported that Chief Operating Officer Ian Michael Estepan had 24,799 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units granted on September 3, 2025. The shares were valued at $22.22 per share for this withholding transaction, and Estepan now directly holds 177,184 shares of Sarepta common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Sarepta Therapeutics, Inc. (SRPT) reported that EVP, General Counsel Cristin Rothfuss had 22,025 shares of common stock withheld on September 4, 2026 to pay tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025. After this tax-related disposition, Rothfuss directly holds 115,519 shares of Sarepta common stock. No Rule 10b5-1 trading plan is reported.
Sarepta Therapeutics, Inc. (SRPT) reported that Louise Rodino-Klapac, President, R&D and Tech Ops, had 21,423 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025. This was a disposition of shares for tax payment rather than an open‑market sale, and no Rule 10b5-1 trading plan is reported. After this withholding, she directly held 203,900 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. filed a Form 13F as an institutional investment manager, indicating it is submitting a 13F holdings report. The summary page shows 1 information table entry with an aggregate reported value of $0, and no other included managers listed. The report is signed by Executive Vice President and Chief Financial Officer Ryan Wong.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 5,329,691 shares of Sarepta Therapeutics, Inc. common stock, equal to 5.05% of the class as of June 30, 2026. The reported amount includes Convertible Notes representing 1,004,002 shares of common stock.
Both entities report shared voting power over 4,916,753 shares and shared dispositive power over 5,329,691 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule 13G/A Amendment No. 1 is filed on behalf of both.
State Street Corporation and its affiliate SSGA Funds Management, Inc. report significant beneficial ownership of Sarepta Therapeutics common stock. State Street and related entities report beneficial ownership of 8,916,103 shares, representing 8.4% of the common stock, with 8,642,126 shares having shared voting power and all 8,916,103 shares having shared dispositive power and no sole voting or dispositive power.
Separately, SSGA Funds Management, Inc. reports beneficial ownership of 6,285,547 shares, or 6% of the class, with shared voting power over 6,271,147 shares and shared dispositive power over 6,285,547 shares. The securities are held through various State Street investment adviser and bank subsidiaries identified in the filing.
Sarepta Therapeutics reported Q2 2026 results with total revenues of $401.3 million, down 34% year over year. The decline mainly reflects lower ELEVIDYS sales under an ambulatory-only label and the absence of a prior-year Roche milestone, partly offset by higher contract manufacturing and $10.0 million of license revenue. Net product revenue was $328.7 million, including $230.6 million from PMO therapies and $98.1 million from ELEVIDYS.
GAAP operating income was $13.3 million and non-GAAP operating income $86.5 million, while GAAP net loss was $4.9 million and non-GAAP net income $78.6 million ($0.64 per diluted share). For the first half of 2026, revenues were $1.13 billion and GAAP net income $326.1 million in a period that also featured sharply lower R&D and SG&A expenses and higher Roche collaboration revenue.
The company ended June 30, 2026 with approximately $945.0 million in cash, cash equivalents, restricted cash and investments. Full-year 2026 total net product revenue guidance was narrowed to $1.2–$1.3 billion, and combined non-GAAP R&D and SG&A expense guidance to $800.0–$850.0 million. Sarepta also recorded a $39.0 million litigation contingency charge related to potential patent settlements, appointed Michael Severino, MD, as CEO, advanced its Huntington’s disease siRNA program, and reported regulatory progress for AMONDYS 45, VYONDYS 53 and gene therapy ELEVIDYS.
Sarepta Therapeutics, a commercial-stage rare disease biotech focused on RNA and gene therapies, reported Q2 2026 total revenues of $401.3 million, down from $611.1 million a year earlier. The quarter showed a small net loss of $4.9 million (basic and diluted loss per share of $0.05), compared with net income of $196.9 million in Q2 2025. For the first six months of 2026, total revenues were $1.13 billion and net income was $326.1 million (basic EPS $3.10), versus a loss of $250.6 million in the prior-year period. Results include a $39.0 million litigation contingency charge and $11.6 million write-down of obsolete ELEVIDYS inventory.
Net product revenues for the first half of 2026 were $659.2 million, including $459.1 million from PMO exon-skipping products and $200.1 million from ELEVIDYS. Collaboration and other revenue benefited from the Roche agreement, with $365.0 million recognized in the first half, including $325.0 million from an unexercised option and a $40.0 million milestone for the first commercial patient in Japan. As of June 30, 2026, Sarepta held $945.0 million in cash, cash equivalents, restricted cash and investments and total stockholders’ equity of $1.53 billion, and believed available resources and its revolving credit facility are sufficient to fund its operational plan for at least twelve months. ELEVIDYS carries a boxed warning for acute liver injury and is currently labeled only for ambulatory patients; Sarepta is running additional studies, including sirolimus-based immunosuppression for non-ambulatory patients, and intends to discuss a potential path to resume dosing in that population with the FDA.